These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12014809)

  • 1. Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease.
    Furlong T; Leisenring W; Storb R; Anasetti C; Appelbaum FR; Carpenter PA; Deeg HJ; Doney K; Kiem HP; Nash RA; Sanders JE; Witherspoon R; Thompson D; Martin PJ
    Biol Blood Marrow Transplant; 2002; 8(4):206-12. PubMed ID: 12014809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA).
    Vogelsang GB; Wolff D; Altomonte V; Farmer E; Morison WL; Corio R; Horn T
    Bone Marrow Transplant; 1996 Jun; 17(6):1061-7. PubMed ID: 8807115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two cases of cutaneous chronic graft versus host disease in treatment with psoralen plus ultraviolet-A-bath photochemotherapy.
    Hoffner MV; Carrizosa Esquivel A; Pulpillo Ruiz A; Herrera Saval A; Conejo-Mir J; Camacho FM
    J Drugs Dermatol; 2009 Nov; 8(11):1027-9. PubMed ID: 19894371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psoralen plus ultraviolet-A-bath photochemotherapy as an adjunct treatment modality in cutaneous chronic graft versus host disease.
    Leiter U; Kaskel P; Krähn G; Gottlöber P; Bunjes D; Peter RU; Kerscher M
    Photodermatol Photoimmunol Photomed; 2002 Aug; 18(4):183-90. PubMed ID: 12390673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Photochemotherapy (PUVA) of acute graft-versus-host disease].
    Reinauer S; Lehmann P; Plewig G; Heyll A; Söhngen D; Hölzle E
    Hautarzt; 1993 Nov; 44(11):708-12. PubMed ID: 8276589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PUVA therapy for cutaneous acute graft-versus-host disease--a case report].
    Inamitsu T; Inoue M; Akiyoshi H; Honda K; Shibuya T; Nakayama H; Ueda K
    Rinsho Ketsueki; 1995 Nov; 36(11):1321-5. PubMed ID: 8691576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of acute graft-versus-host disease with PUVA (psoralen and ultraviolet irradiation): results of a pilot study.
    Wiesmann A; Weller A; Lischka G; Klingebiel T; Kanz L; Einsele H
    Bone Marrow Transplant; 1999 Jan; 23(2):151-5. PubMed ID: 10197800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PUVA therapy for drug-resistant graft-versus-host disease.
    Atkinson K; Weller P; Ryman W; Biggs J
    Bone Marrow Transplant; 1986 Dec; 1(2):227-36. PubMed ID: 3502781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation.
    Mielcarek M; Burroughs L; Leisenring W; Diaconescu R; Martin PJ; Sandmaier BM; Maloney DG; Maris MB; Chauncey TR; Shizuru JA; Blume KG; Hegenbart U; Niederwieser D; Forman S; Bruno B; Woolfrey A; Storb R
    Br J Haematol; 2005 May; 129(3):381-91. PubMed ID: 15842663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation.
    Massenkeil G; Rackwitz S; Genvresse I; Rosen O; Dörken B; Arnold R
    Bone Marrow Transplant; 2002 Dec; 30(12):899-903. PubMed ID: 12476283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease.
    Eppinger T; Ehninger G; Steinert M; Niethammer D; Dopfer R
    Transplantation; 1990 Nov; 50(5):807-11. PubMed ID: 2238056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease.
    MacMillan ML; Weisdorf DJ; Davies SM; DeFor TE; Burns LJ; Ramsay NK; Wagner JE; Blazar BR
    Biol Blood Marrow Transplant; 2002; 8(1):40-6. PubMed ID: 11858189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracorporeal photochemotherapy for treatment of drug-resistant graft-vs.-host disease.
    Smith EP; Sniecinski I; Dagis AC; Parker PM; Snyder DS; Stein AS; Nademanee A; O'Donnell MR; Molina A; Schmidt GM; Stepan DE; Kapoor N; Niland JC; Forman SJ
    Biol Blood Marrow Transplant; 1998; 4(1):27-37. PubMed ID: 9701389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies.
    Sakellari I; Batsis I; Bousiou Z; Mallouri D; Constantinou V; Gavriilaki E; Smias C; Yannaki E; Kaloyannidis P; Papaioannou G; Stavroyianni N; Syrigou A; Sotiropoulos D; Fylaktou A; Tsompanakou A; Saloum R; Anagnostopoulos A
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):658-666. PubMed ID: 28716402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of acute cutaneous graft-versus-host disease mimicking psoriasis vulgaris.
    Matsushita T; Hasegawa M; Shirasaki F; Fujimoto M; Yamazaki H; Sato S; Takehara K
    Dermatology; 2008; 216(1):64-7. PubMed ID: 18032902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.
    Spitzer TR; McAfee S; Sackstein R; Colby C; Toh HC; Multani P; Saidman S; Weyouth DW; Preffer F; Poliquin C; Foley A; Cox B; Andrews D; Sachs DH; Sykes M
    Biol Blood Marrow Transplant; 2000; 6(3A):309-20. PubMed ID: 10905768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bath PUVA therapy in pediatric patients with drug-resistant cutaneous graft-versus-host disease.
    Bonanomi S; Balduzzi A; Tagliabue A; Biagi E; Rovelli A; Corti P; Crippa D; Uderzo C
    Bone Marrow Transplant; 2001 Sep; 28(6):631-2. PubMed ID: 11607781
    [No Abstract]   [Full Text] [Related]  

  • 20. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.
    MacMillan ML; Weisdorf DJ; Wagner JE; DeFor TE; Burns LJ; Ramsay NK; Davies SM; Blazar BR
    Biol Blood Marrow Transplant; 2002; 8(7):387-94. PubMed ID: 12171485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.